NCI is adding yet another trial of VX 970 and whole brain radiation in patients with Non-small cell lung cancer (stage 4). NCI guys must be in love with this thing. I understand these are early studies and future of VX 970 is s unknown. AZN is also developing AZD 6738 and it is a good thing that a big pharma with deep oncology interest is working on a similar sister compound. It will be nice if VRTX partner this compound to accelerate its development.
Revlimid is focus only for multiple myeloma and myelodysplastic syndrome. VX 970 will have potential to cover all the big solid malignancies like NSCL cancer, Colon cancer and Breast cancer. This is bigger than immune oncology #$%$.
few day ago I reported that drug response rate was extended from 6 months to 1 year. No brainer that drug is a high fly. This is a huge drug because it combines with Topo I i.e will be a first line therapy very soon. CELG Revlimid is #$%$ in front of VX 970 potential in my opinion.
VX970 trial has an update. CRR extended from 28 weeks to 1 year. Study seems to be more focus towards triple negative breast cancer than NSCL cancer ( my take home). Additionally NCI has sponsored three phase II trials in SCLC, Non HPV head and neck I.e squamous cell, and urothelial tumors. This is Avastin of VRTX.